FY2027 Earnings Forecast for ATNM Issued By HC Wainwright

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – HC Wainwright issued their FY2027 earnings per share estimates for Actinium Pharmaceuticals in a report released on Tuesday, March 25th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($1.13) per share for the year. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ FY2028 earnings at ($1.24) EPS.

Actinium Pharmaceuticals Stock Down 4.2 %

Shares of ATNM opened at $1.81 on Friday. The stock’s 50-day moving average price is $1.25 and its 200 day moving average price is $1.45. The firm has a market capitalization of $56.46 million, a price-to-earnings ratio of -1.30 and a beta of 0.10. Actinium Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $10.24.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Vontobel Holding Ltd. bought a new stake in shares of Actinium Pharmaceuticals in the 4th quarter valued at approximately $32,000. Sei Investments Co. bought a new stake in shares of Actinium Pharmaceuticals in the 4th quarter worth about $62,000. Barclays PLC increased its position in shares of Actinium Pharmaceuticals by 323.0% during the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after purchasing an additional 32,784 shares in the last quarter. Bank of America Corp DE lifted its holdings in Actinium Pharmaceuticals by 76.6% during the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock valued at $99,000 after purchasing an additional 34,176 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in Actinium Pharmaceuticals in the third quarter valued at about $112,000. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).